The combination of thiamine, ascorbic acid, and corticosteroids is a promising new therapy for sepsis resuscitation but currently lacks robust evidence to support its widespread use. The potential effectiveness of this medication combination is rooted in biologic plausibility and supported by small clinical trials of the various individual components. Randomized data to confirm or refute the observational evidence for the drug combination are needed, and several clinical trials are ongoing or planned in the near future. We therefore anticipate a timely answer to the question of whether thiamine, ascorbic acid, and corticosteroids will play a role in the evolution of sepsis therapies. Our study, the Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial is a multi-center randomized clinical trial in the United States aimed at assessing the effect of the drug combination on organ function and other outcomes in septic shock. The ACTS trial is coordinated by the Center for Resuscitation Science at Beth Israel Deaconess Medical Center (BIDMC) in Boston, MA, USA and is currently enrolling.

Read More